Olaparib Tablets

The first PARP inhibitor has the potential to be a broad-spectrum antitumor drug

Olaparib Tablets, as a polyladenosine diphosphate-ribose polymerase 〔PARP〕 inhibitor, inhibit the activity of the PARP enzyme, hindering the DNA repair ability of tumor cells is hindered, which leads to the death of tumor cells. Olaparib Tablets are initially indicated for BRCA-mutated advanced ovarian cancer, and subsequently expanded to ovarian cancer, breast cancer, pancreatic cancer, prostate cancer and other malignancies. It is a first-line therapeutic agent for breast cancer and a first-line maintenance therapy for ovarian cancer recommended by the NCCN clinical guidelines.

Indications:

This product is indicated for maintenance treatment in newly treated adult patients with advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer carrying germ-line or somatic BRCA mutations (gBRCAm or sBRCAm) after first-line platinum-containing chemotherapy has achieved a complete or partial response. 

Maintenance therapy in adult patients with platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer after achieving a complete or partial response to platinum-containing chemotherapy.

STRENGTH:

100mg/tablet

150mg/tablet